December 5: The Week in Cancer News
Research continues to show efficacy of HPV vaccines at preventing cervical cancer, and the FDA approves an immunotherapy for use before and after surgery for stomach cancers.
Research continues to show efficacy of HPV vaccines at preventing cervical cancer, and the FDA approves an immunotherapy for use before and after surgery for stomach cancers.
The inaugural AACR Pediatric Cancer Progress Report details advances in treating children and adolescents with cancer and remaining gaps in care.
Lisocabtagene maraleucel was granted approval for adults with treatment-resistant marginal zone lymphoma. The U.S. Food and Drug Administration (FDA) has approved lisocabtagene maraleucel (Breyanzi) for adults with relapsed or refractory marginal zone lymphoma (MZL)...
Pirtobrutinib was approved for certain relapsed/refractory chronic lymphocytic leukemias or small lymphocytic lymphomas. The U.S. Food and Drug Administration (FDA) has granted traditional approval to pirtobrutinib (Jaypirca) for adults with relapsed or refractory chronic...
Durvalumab was approved as neoadjuvant and adjuvant treatment with chemotherapy for resectable gastric or gastroesophageal junction cancer. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) as a neoadjuvant and adjuvant therapy...
The combination therapy is approved for pre- and post-surgery bladder cancer treatment. The U.S. Food and Drug Administration (FDA) has approved a combination therapy that uses either pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph...
Steve Schneible covered the AACR Philadelphia Marathon Weekend live, including updates from his own participation in the half marathon.
In November, the AACR’s journal editors highlighted studies on sucralose limiting immunotherapy, benefits of caloric restriction, and more.
Shawn Lee, MD, PhD, an AACR-St. Baldrick’s Foundation Grantee, is working to personalize therapies for children with acute lymphoblastic leukemia.
The FDA has converted the accelerated approval of tarlatamab-dlle to a full approval for previously treated adults with extensive-stage small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval...